| Stock | PriceCurrent trading price. | Market CapTotal market capitalization. | FKPrice to Earnings ratio. | PD/DDPrice to Book ratio. | EV/EBITDAEnterprise Value / EBITDA. | ROICReturn on Invested Capital. | WACCWeighted Average Cost of Capital (WACC). | PUSLAFinancial health score (0-100). | DamodaranValuation score. | Intrinsic ValueFair value via DCF model. | Potential %Expected upside potential %. | Dalio RiskDalio Debt Cycle Score | Debt/EquityDebt to Equity ratio. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
HIK
|
1,664.00 | 3.4B | 12.83 | 1.81 | 8.15 | 15.3% | 13.0% | 66 | 34 | 2,003.96 | +14.7% | 64 | 0.61 |
|
SN
|
1,068.00 | 8.9B | 18.91 | 2.23 | 9.52 | 10.2% | 13.1% | 61 | 31 | 990.47 | -5.2% | 70 | 0.63 |
|
GSK
|
1,916.00 | 76.8B | 13.43 | 4.75 | 8.44 | 25.8% | 10.4% | 58 | 46 | 1,784.17 | -4.6% | 58 | 1.10 |
|
AZN
|
12,476.00 | 193.5B | 25.30 | 5.32 | 14.42 | 17.3% | 11.3% | 46 | 32 | 7,290.97 | -31.2% | 69 | 0.61 |
|
CRDA
|
3,282.00 | 4.6B | 73.89 | 2.09 | 19.93 | 8.9% | 14.0% | 41 | 25 | 1,859.04 | -31.2% | 72 | 0.32 |
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.